Financial Performance - The company's operating revenue for 2024 reached ¥471,510,162.35, representing an 18.63% increase compared to ¥397,453,269.86 in 2023[6]. - Net profit attributable to shareholders for 2024 was ¥122,557,731.65, up 17.09% from ¥104,667,468.56 in 2023[6]. - The net profit after deducting non-recurring gains and losses was ¥116,677,414.94, reflecting a 15.02% increase from ¥101,439,037.43 in 2023[6]. - Cash flow from operating activities saw a significant increase of 107.35%, totaling ¥167,156,275.90 compared to ¥80,615,439.66 in 2023[6]. - The total assets at the end of 2024 amounted to ¥1,485,991,744.60, marking a 10.82% increase from ¥1,340,950,789.82 at the end of 2023[6]. - The company reported a basic earnings per share of ¥1.22 for 2024, a 7.96% increase from ¥1.13 in 2023[6]. - The weighted average return on equity decreased to 9.42% in 2024 from 10.77% in 2023, indicating a decline of 1.35%[6]. - The company achieved operating revenue of 471.51 million yuan, representing a year-on-year growth of 18.63%[37]. - Net profit attributable to shareholders reached 122.56 million yuan, an increase of 17.09% year-on-year[37]. Research and Development - R&D expenses amounted to 27.78 million yuan, accounting for 5.89% of operating revenue, with a year-on-year growth of 47.44%[37]. - The company has 17 ongoing R&D projects, including 4 new products, targeting various therapeutic areas such as antiviral and anti-inflammatory[56]. - The company has increased its R&D investment, focusing on new product and process development, and has established partnerships with domestic universities and research institutions[71]. - The company’s R&D investment increased by 47.44% year-on-year, focusing on technology innovation and product development[55]. - The company is committed to innovation and plans to accelerate product and process research and development to meet changing market demands[119]. Market Strategy and Expansion - The company is actively expanding its market presence both domestically and internationally, utilizing trade partnerships and direct sales strategies[46]. - The company is positioned to benefit from national healthcare policies aimed at optimizing cost structures and enhancing product quality and innovation[35]. - The company aims to strengthen its position in the global market, particularly in India, Mexico, and Brazil, while increasing investments in the US and Europe to enhance its international presence[119]. - The company plans to build a sales team that is better suited for international and formulation markets, improving management efficiency and responsiveness to market changes[121]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 100 million allocated for potential deals in 2024[169]. Corporate Governance - The financial report emphasizes the importance of accurate and complete financial disclosures, with all board members present for the meeting[4]. - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, enhancing the quality of information disclosure[138]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal requirements and effective decision-making[141]. - The company has implemented a transparent and effective performance evaluation system for senior management, linking performance to compensation[143]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring a complete and independent business system[150]. Risk Management - The company faces product concentration risk, with major products including aluminum sulfate, aminophenol, atorvastatin calcium, and PHBA, which could adversely affect operations if market demand changes[124]. - The company is aware of the risks associated with fundraising projects not meeting expectations and is committed to prudent project implementation and timely adjustments based on external changes[128]. - The company is closely monitoring exchange rate fluctuations and has implemented risk management strategies to mitigate potential impacts on its export revenues[131]. - The company has a high concentration of raw material procurement, which poses risks if supplier relationships deteriorate or if raw material prices increase significantly[126]. Shareholder Returns - The company plans to distribute a cash dividend of 1.70 RMB per 10 shares (including tax) and to increase capital by 4.8 shares per 10 shares from capital reserves[4]. - The profit distribution plan for 2023 includes a cash dividend of 5 RMB per 10 shares and a capital reserve increase of 4.8 shares per 10 shares, with a total cash dividend amounting to 17,451,010 RMB[193]. - The total distributable profit for the company was 451,214,746.67 RMB, with the cash dividend representing 100% of the profit distribution[193]. - The company has a total of 102,653,000 shares as the basis for its profit distribution plan[193]. Employee Management - The company has increased the recruitment of talent with bachelor's degrees or higher by nearly 20% year-on-year, enhancing the overall educational level of employees[62]. - The company achieved a training plan completion rate of 100%, ensuring all employees received training during the reporting period[190]. - The company implemented a restricted stock incentive plan during the reporting period, combining short-term and long-term compensation to enhance employee motivation[189]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to RMB 667.34 million[175]. Sustainability and Compliance - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 20% by 2025[168]. - The company is committed to ensuring compliance with relevant laws and regulations, as stated by its management team[4]. - The company has established a comprehensive waste treatment system with a capacity of 1,500 tons/day and a RTO exhaust gas treatment system of 20,000 cubic meters/hour[74]. - The company has not experienced major safety incidents during the reporting period and continues to enhance its EHS management system to mitigate safety and environmental risks[129].
海森药业(001367) - 2024 Q4 - 年度财报